NEW YORK, Nov. 7 — San Diego-based GeneFormatics on Wednesday said that it has added Edward Lanphier to its board of directors.
Lanphier, the founder, president and CEO of Sangamo BioSciences, will assist the privately-held structural proteomics firm with business development and management.
Lanphier founded Sangamo BioSciences in 1997. Before that he was a senior executive at Somatix Therapy Corporation, vice president for corporate development at Synergen, and the former president and CEO of BioGrowth.
He is also on the Biotechnology Industry Organization board of directors.
Large Scale Biology has named John D. Fowler as president and a director, and Ronald J. Artale as chief financial officer, the company said on Nov. 6.
Fowler will help LSB evolve from a platform technology firm to a commercial product company, CEO Robert Erwin said in a statement.
Fowler founded the Healthcare banking group at Salomon Brothers, and prior to his appointment at LSB was managing director of the Healthcare Group at J.P. Morgan.
Artale was previously vice president, chief financial officer, treasurer, and a director of Addition Technology, a private investment firm. He was also executive vice president of VMA, a Chicago venture-capital firm. He will replace William Pfann, who is retiring.
Paradigm Genetics has formed a scientific advisory board to oversee its metabolomics efforts in human health, agriculture, and nutrition, the firm said on Nov. 5. The Research Triangle Park, NC –based company will rely upon the board for guidance as it expands its achievements in agricultural metabolomics to these other fields.
The board includes six veterans in proteomics, biostatistics, toxicology, and bioinformatics. Respectively, they are: Ralph Bradshaw, professor of physiology, biophysics, anatomy, and neurobiology at the University of California, Irvine; John Hartigan, acting chair of the biostatistics department at Yale University; Ian Jardine, president of Thermo Finnigan; A. Ian Scott, a leader in vitamin B-12 synthesis and NMR methods and distinguished professor of chemistry at Texas A&M; and Evgeni Selkov, a senior scientist in mathematics and computer science at Argonne National Laboratory.
Athersys announced that William (B.J.) Lehmann, Jr., has joined the firm as vice president of corporate development and Youssef Bennani as director of medicinal chemistry.
Lehman will help the Cleveland-based functional genomics and biopharmaceutical company develop new business and corporate partnerships, Athersys said in a statement.
Bennani, meanwhile, will oversee the firm’s internal and external drug discovery programs for small molecule therapies.
Lehmann was previously associate principal at the consulting firm McKinsey & Company where he helped companies launch new medical products and develop commercialization strategies. Bennani was senior group leader in neurological and urological disease research at Abbott Laboratories, with experience in oncology, metabolic and infectious disease research.
Berkeley, Calif.-based start-up Plexxikon has named Kathleen Sereda Glaub to be president and CFO and has brought aboard Michael Milburn as senior vice president and head of research.
Glaub was formerly senior vice president and chief financial officer at Cell Genesys and has also worked at Genentech and Intel. Milburn formerly directed bioinformatics, computational chemistry, and crystallography at Structural Genomix, where he was vice president of structural biology.
Biogen has appointed Robert Hamm as senior vice president, international, one of a number of senior changes to the company’s international executive team, the firm said on Nov. 2. Hamm will replace Mark Leuchtenberger , who said he would resign at the end of the year.
The company also appointed Guy-Charles Fanneau dela Horie vice president of international strategic commercial operations-International. Patrick Vink has been appointed vice president of sales for international affiliates.
Hamm, who joined Cambridge, Mass.-based Biogen in 1994, was most recently vice president of sales and marketing.
Fanneau dela Horie has worked in a number of positions since joining Biogen in 1995 while Vink joined Biogen in 2000 as country manager for Germany.
Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] .
PEOPLE, a roundup of personnel comings and goings in the genomics sector, appears every Wednesday.